ArticleNanomaterials (Basel, Switzerland)2026
Extracellular Vesicles Derived from
Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aim of the studyThis study aims to isolate extracellular vesicles derived from
methodsEBDEVs were isolated by differential and density gradient ultracentrifugation, then characterized for morphology, size, stability, and composition. Their anti-inflammatory activity was assessed in LPS-stimulated RAW264.7 macrophages. In vivo, acute UC was induced in C57BL/6 mice by 2.5% DSS. Disease severity, intestinal barrier integrity, TLR4/MyD88/NF-κB pathway activation, and gut microbiota composition were evaluated.
resultsEBDEVs exhibited a typical spherical structure and were rich in bioactive components such as lipids, flavonoids, and terpenoids. Macrophages readily internalized them and significantly inhibited LPS-induced NO production. In UC mice, EBDEVs ameliorated weight loss, colon shortening, and tissue damage, while reducing serum inflammatory cytokines. EBDEVs restored intestinal barrier function by regulating tight junction proteins. Mechanistically, EBDEVs suppressed the activation of TLR4/MyD88/NF-κB and downstream NLRP3 inflammasome inflammatory signaling cascades, and remodeled the dysregulated gut microbiota structure.
conclusionsEBDEVs alleviate DSS-induced UC in mice by repairing the intestinal barrier, inhibiting inflammatory pathways, and modulating gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.